candesartan has been researched along with Atherosclerotic Parkinsonism in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Interestingly, chronic administration of candesartan to normal rats induced a marked increase in dopamine D1 and a decrease in dopamine D2 receptor expression." | 1.40 | Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA. ( Dominguez-Meijide, A; Garrido-Gil, P; Guerra, MJ; Labandeira-Garcia, JL; Sierrra-Paredes, G; Villar-Cheda, B, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dominguez-Meijide, A | 1 |
| Villar-Cheda, B | 1 |
| Garrido-Gil, P | 1 |
| Sierrra-Paredes, G | 1 |
| Guerra, MJ | 1 |
| Labandeira-Garcia, JL | 1 |
1 other study available for candesartan and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Corpus Striatum; Dise | 2014 |